TherapeuticsMD (TXMD) – Research Analysts’ Weekly Ratings Changes

TherapeuticsMD (NASDAQ: TXMD) recently received a number of ratings updates from brokerages and research firms:

• 9/10/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/4/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/29/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/23/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/17/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/11/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 8/5/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 7/30/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 7/24/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 7/18/2024 – TherapeuticsMD is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

TherapeuticsMD Stock Down 0.6 %

Shares of NASDAQ:TXMD opened at $1.78 on Wednesday. The firm’s 50 day simple moving average is $1.75 and its 200-day simple moving average is $1.98. TherapeuticsMD, Inc. has a one year low of $1.43 and a one year high of $3.73.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter. The firm had revenue of $0.23 million for the quarter.

Institutional Investors Weigh In On TherapeuticsMD

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TXMD. Prosperity Consulting Group LLC purchased a new stake in TherapeuticsMD during the 1st quarter valued at about $56,000. ADAR1 Capital Management LLC acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth about $612,000. Finally, Clearline Capital LP boosted its position in TherapeuticsMD by 18.9% in the second quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after buying an additional 101,282 shares during the last quarter. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.